ClinicalTrials.gg
Not yet recruitingNCT07825077Updated Sep 21, 2026

Effects of AI Dialogue-Based Scenario Simulation on Students' Flow and Learning Performance

An interventional study of Gamified Feedback and Conventional Formative Feedback in Nursing Education, sponsored by Chang Gung University of Science and Technology. Not yet recruiting at 1 site in Taiwan. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-21.

Sponsored by Chang Gung University of Science and Technology · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
91
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study examines the effects of an AI dialogue-based scenario simulation integrated with concept mapping and post-dialogue feedback on nursing students' learning. Nursing students will participate in pediatric care scenarios using standardized AI-supported dialogues. Two feedback approaches will be compared: gamified feedback and conventional formative feedback without gamification elements. The study will examine students' flow experience and learning performance and explore how collaborative processes and interaction mechanisms may contribute to these outcomes. The findings are expected to provide evidence on how different feedback approaches influence students' engagement and learning during AI-supported scenario simulation.

02

Conditions studied

  • Nursing Education
03

In context

Lead sponsor

Chang Gung University of Science and Technology is the lead sponsor of 43 studies on the registry; 15 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Undergraduate nursing students enrolled in the designated nursing course during the study period.

  • Aged 18 years or older.
  • Willing to participate and providing .

Exclusion criteria

Exclusion Criteria:

- Students who decline or do not provide .

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
91 participants (estimated)

Study arms

  • Experimental
    Gamified Feedback Group

    Participants receive a concept-mapping-integrated AI dialogue-based scenario simulation followed by gamified feedback. The feedback includes gamification elements such as points, levels, progress indicators, and mission-based features.

    Behavioral: Gamified Feedback

  • Active comparator
    Conventional Formative Feedback Group

    Participants receive the same concept-mapping-integrated AI dialogue-based scenario simulation followed by conventional formative feedback without gamification elements.

    Behavioral: Conventional Formative Feedback

Interventions

  • BehavioralGamified Feedback

    Gamified feedback is delivered following the AI dialogue-based scenario simulation and includes game-related elements such as points, levels, progress indicators, and mission-based features.

  • BehavioralConventional Formative Feedback

    Conventional formative feedback is delivered following the same AI dialogue-based scenario simulation without gamification elements.

06

What researchers measure

Primary outcomes

  1. Flow Experience

    Flow experience will be assessed using the 8-item Flow Experience Questionnaire developed by Pearce et al. (2005). Each item is rated on a 5-point Likert scale ranging from 1 (strongly disagree) to 5 (strongly agree). Higher scores indicate a greater level of flow experience. Descriptive statistics will be used to examine the distribution and change in flow scores, missing data, and internal consistency.

    Time frame: Baseline (before the intervention) and immediately after completion of the intervention (approximately Week 18).

  2. Academic Learning Performance

    Academic learning performance will be assessed using students' course midterm and final examination scores. Higher scores indicate better academic performance.

    Time frame: At approximately Week 9 (midterm examination) and Week 18 (final examination) of the academic semester.

Secondary outcomes

  1. Intrinsic Motivation

    Intrinsic motivation will be assessed using a 25-item version of the Intrinsic Motivation Inventory (IMI), based on the IMI framework of McAuley et al. (1989) and the version adapted by Yin et al. (2021). Items are rated on a 7-point Likert scale from 1 (strongly disagree) to 7 (strongly agree). The instrument assesses five dimensions: interest/enjoyment, pressure/tension, perceived choice, perceived competence, and perceived value. Reverse-coded items will be recoded before analysis, and each subscale score will be calculated as the mean of its constituent items.

    Time frame: Baseline (before the intervention) and immediately after completion of the intervention (approximately Week 18).

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2026; primary completion for Jan 2027, 3 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2026
First posted
Sep 17, 2026
StartEst.
Sep 21, 2026
Primary completionEst.
Jan 5, 2027
CompletionEst.
Jan 5, 2027
Last update
Sep 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07825077
Lead sponsor
Chang Gung University of Science and Technology
Responsible party
Sponsor
First posted
Sep 17, 2026
Start date
Sep 21, 2026 (estimated)
Primary completion
Jan 5, 2027 (estimated)
Completion
Jan 5, 2027 (estimated)
Last update
Sep 21, 2026

Study contacts

Bao Huan Yang, PhD
Contact
bhyang@mail.cgust.edu.tw
+88632118999 ext 3401

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion